text:
Edward Acosta Pharm.D.
eacosta@uab.edu
Senior Scientist (C), Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center (CAMBAC) , School of Medicine
Senior Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine
Associate Scientist (C), Center for AIDS Research , School of Medicine
Senior Scientist (C), Cystic Fibrosis Research Center , School of Medicine
Assistant Professor (S), Pediatrics , School of Medicine
Senior Scientist (C), Center for Clinical and Translational Science (CCTS) , General Clinical Research Center
Senior Scientist (C), Center for Women's Reproductive Health , General Clinical Research Center
Professor (P), Clinical Pharmacology and Toxicology , Pharmacology and Toxicology
Division Director, Clinical Pharmacology and Toxicology , Pharmacology and Toxicology
2022 Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate 2022
2022 Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC Cancer. 22. 2022
2022 Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis. Pediatric pulmonology. Supplement. 57:2745-2753. 2022
2022 Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior. Frontiers in Pharmacology. 13. 2022
2022 Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial. Lancet HIV. 9:e332-e340. 2022
2022 Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clinical Infectious Diseases. 74:865-870. 2022
2022 Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. Journal of Cystic Fibrosis. 21:e8-e10. 2022
2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Research. 23. 2021
2021 A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.. Journal of Infectious Diseases. 224:648-656. 2021
2021 A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons with HIV-1 on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases. 224:648-656. 2021
2021 Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. Clinical Pharmacology and Therapeutics. 110:64-68. 2021
2021 Implications of Efavirenz Pharmacogenetics When Switching from Efavirenz- to Dolutegravir-containing Antiretroviral Regimens. Clinical Infectious Diseases. 72:1820-1822. 2021
2021 Pharmacokinetics and safety of maraviroc in neonates. AIDS. 35:419-427. 2021
2021 Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living with Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of the Pediatric Infectious Diseases Society. 10:201-204. 2021
2020 Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097 2020
2020 Genital shedding of human immunodeficiency virus Type-1 (HIV) when antiretroviral therapy suppresses HIV replication in the plasma. Journal of Infectious Diseases. 222:777-786. 2020
2020 Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. Journal of Cystic Fibrosis. 19:742-745. 2020
2020 Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer. Cells. 9. 2020
2020 Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110) 2020
2020 Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: Protocol for a randomised, double-blind,placebo-controlled, treatment trial. BMJ Open. 10. 2020
2020 Advances in the development of therapeutics for cytomegalovirus infections. Journal of Infectious Diseases. 221:32-44. 2020
2020 Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: Results of the impaact p1093 study. Journal of the Pediatric Infectious Diseases Society. 9:159-165. 2020
2019 Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110 2019
2019 Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 33:2197-2203. 2019
2019 Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing 2019
2019 Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. AIDS Research and Human Retroviruses. 35:691-697. 2019
2019 Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353. Journal of Antimicrobial Chemotherapy. 74:1376-1380. 2019
2019 Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial Agents and Chemotherapy. 63. 2019
2019 Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation. 25:515-521. 2019
2019 Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch. Ultrasound in Medicine and Biology. 45:513-525. 2019
2018 Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. Lancet HIV. 5:e715-e722. 2018
2018 The control of HIV after antiretroviral medication pause (CHAMP) study: Posttreatment controllers identified from 14 clinical studies. Journal of Infectious Diseases. 218:1954-1963. 2018
2018 Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infectious Diseases. 5. 2018
2018 HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. Journal of Clinical Investigation. 128:4074-4085. 2018
2018 Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. AIDS. 32:1389-1401. 2018
2018 ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mL. Clinical Infectious Diseases. 66:1689-1697. 2018
2018 Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clinical Infectious Diseases. 66:1794-1797. 2018
2018 Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatric pulmonology. Supplement. 53:E6-E8. 2018
2018 Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 32:729-737. 2018
2018 Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenetics and Genomics. 28:179-187. 2018
2018 Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 32:2507-2516. 2018
2018 HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy. AIDS. 32:2151-2159. 2018
2017 Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults. Journal of the Pediatric Infectious Diseases Society. 6:294-296. 2017
2017 Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. Retrovirology. 14. 2017
2017 Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. Journal of Infectious Diseases. 215:1725-1733. 2017
2017 Current status of the pharmacokinetics and pharmacodynamics of HIV-1 entry inhibitors and HIV therapy. Current Drug Metabolism. 18:769-781. 2017
2017 Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 8:17216-17228. 2017
2016 Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults 2016
2016 Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults 2016
2016 Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults. Journal of the Pediatric Infectious Diseases Society. 5:131-137. 2016
2016 Pilot evaluation of ivacaftor for chronic bronchitis 2016
2016 Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens. Journal of Clinical Pharmacology. 56:492-496. 2016
2015 Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. Journal of the Pediatric Infectious Diseases Society. 4:e76-e83. 2015
2015 A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. Journal of the Pediatric Infectious Diseases Society. 5:53-62. 2015
2015 Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clinical Infectious Diseases. 61:1179-1188. 2015
2015 Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. Obstetrical and Gynecological Survey. 70:489-490. 2015
2015 Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 25:450-461. 2015
2015 Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. Journal of Clinical Pharmacology. 55:748-756. 2015
2015 The authors reply. New England Journal of Medicine. 372:2463. 2015
2015 Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. American Journal of Obstetrics and Gynecology. 212:812.e1-812.e6. 2015
2015 Valganciclovir for symptomatic congenital cytomegalovirus disease. New England Journal of Medicine. 372:933-943. 2015
2015 Helicase-primase as a target of new therapies for herpes simplex virus infections. Clinical Pharmacology and Therapeutics. 97:66-78. 2015
2015 Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients. AIDS. 29:1113-1115. 2015
2015 Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents : Forty-eight-week results from IMPAACT P1093 2015
2014 Pharmacokinetic Enhancers in HIV Therapeutics. Clinical Pharmacokinetics. 53:865-872. 2014
2014 Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-Naïve patients. Clinical Pharmacokinetics. 53:361-371. 2014
2014 Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 9. 2014
2014 La utilización del software educativo en el desarrollo de la educación ambiental en Cuba 2014
2014 Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clinical Infectious Diseases. 58:413-422. 2014
2014 A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma 2014
2014 Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Journal of Clinical Pharmacology. 54:1063-1071. 2014
2014 Raltegravir pharmacokinetics in neonates following maternal dosing 2014
2014 Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. Journal of Antimicrobial Chemotherapy. 69:2175-2182. 2014
2014 The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clinical Pharmacology and Therapeutics. 96:380-389. 2014
2014 Transplacental transfer of azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model. Journal of Infectious Diseases. 209:898-904. 2014
2013 Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic study. PLoS One. 8. 2013
2013 Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study 2013
2013 Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. Journal of Infectious Diseases. 208:884-891. 2013
2013 Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. Journal of Infectious Diseases. 208:662-671. 2013
2013 Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. British Journal of Clinical Pharmacology. 75:997-1006. 2013
2013 Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. Journal of Infectious Diseases. 207:709-720. 2013
2013 The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study. Journal of epilepsy. 103:245-253. 2013
2013 Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. AIDS. 27:221-225. 2013
2013 Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.. Adolescent Health, Medicine and Therapeutics. 4:79-87. 2013
2013 Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.. Journal of Experimental Pharmacology. 5:55-64. 2013
2012 Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. AIDS. 26:2257-2259. 2012
2012 Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrobial Agents and Chemotherapy. 56:5938-5945. 2012
2012 Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrobial Agents and Chemotherapy. 56:5374-5380. 2012
2012 Oseltamivir dosing in premature infants. Journal of Infectious Diseases. 206:847-850. 2012
2012 A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathogens. 8. 2012
2012 Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection 2012
2012 Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'. AIDS. 26:397-398. 2012
2012 Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenetics and Genomics. 22:858-867. 2012
2012 Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. American Journal of Obstetrics and Gynecology. 207:475.e1-475.e14. 2012
2012 Tenofovir: Once-daily dosage in the management of HIV infection 2012
2011 Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 25:2113-2122. 2011
2011 Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposure. Journal of Clinical Pharmacology. 51:1539-1548. 2011
2011 Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrobial Agents and Chemotherapy. 55:4290-4294. 2011
2011 A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet 2011
2011 A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates. Annals of Applied Statistics. 5:551-577. 2011
2010 Determination of appropriate dosing of influenza drugs in pediatric patients. Clinical Pharmacology and Therapeutics. 88:704-707. 2010
2010 Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study. Journal of Infectious Diseases. 202:717-722. 2010
2010 Oseltamivir dosing for influenza infection in premature neonates. Journal of Infectious Diseases. 202:563-566. 2010
2010 Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors 2010
2010 Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical Infectious Diseases. 50:912-919. 2010
2010 A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. AIDS. 24:447-455. 2010
2010 The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.. Journal of Clinical Pharmacology. 50:1050-1055. 2010
2009 13C-5-FU breath test current status and future directions: A comprehensive review 2009
2009 Antiretroviral rounds. Happy 50th? Sedation for colonoscopy in HIV-infected patients.. AIDS clinical care. 21:45-46. 2009
2009 Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. Clinical Infectious Diseases. 48:1138-1151. 2009
2009 Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. Journal of Infectious Diseases. 199:872-880. 2009
2009 Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir 2009
2009 Pharmacologic aspects of new antiretroviral drugs. Current HIV/AIDS Reports. 6:43-50. 2009
2009 Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clinical Trials. 10:181-192. 2009
2009 Electrocardiogram abnormalities with Atazanavir and Lopinavir/Ritonavir. HIV Clinical Trials. 10:328-336. 2009
2009 Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clinical Trials. 10:343-355. 2009
2009 Novel methodology for antiretroviral quantitation in the female genital tract. HIV Clinical Trials. 10:193-199. 2009
2009 Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/ emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). HIV Clinical Trials. 10:160-167. 2009
2009 Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients 2009
2009 Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clinical Trials. 10:41-47. 2009
2008 No residual activity of raltegravir after development of 148 complex mutations in vivo. Journal of the International Association of Providers of AIDS Care. 7:281-282. 2008
2008 Pharmacologic aspects of new antiretroviral drugs. Current Infectious Disease Reports. 10:522-529. 2008
2008 Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine. 14:762-766. 2008
2008 A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma 2008
2008 Pediatric clinical pharmacology and its implications for antiretroviral drug development. Current Opinion in HIV and AIDS. 3:272-276. 2008
2008 Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline. AIDS. 22:957-962. 2008
2008 Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. Journal of Infectious Diseases. 197:1006-1010. 2008
2008 Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186 2008
2008 Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. Journal of Infectious Diseases. 197:836-845. 2008
2008 Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. Journal of Infectious Diseases. 197:867-870. 2008
2008 Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clinical Trials. 9:91-102. 2008
2008 Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus 2008
2007 Cloning and characterization of recombinant rhesus macaque IL-10/Fcala-ala fusion protein: A potential adjunct for tolerance induction strategies. Cytokine. 40:183-192. 2007
2007 Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrobial Agents and Chemotherapy. 51:4297-4302. 2007
2007 Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antiviral Therapy. 12:981-986. 2007
2007 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrobial Agents and Chemotherapy. 51:3104-3110. 2007
2007 Lopinavir/ritonavir pharmacokinetic profile: Impact of sex and other covariates following a change from twice-daily to once-daily therapy. Journal of Clinical Pharmacology. 47:970-977. 2007
2007 Persistence of nevirapine in breast milk after discontinuation of treatment. Clinical Infectious Diseases. 45:391-394. 2007
2007 A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS clinical trials group study A5115. Antiviral Therapy. 12:531-541. 2007
2007 Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma. Rapid Communications in Mass Spectrometry. 21:2087-2094. 2007
2007 Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrobial Agents and Chemotherapy. 51:2208-2210. 2007
2007 Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clinical Pharmacology and Therapeutics. 81:867-872. 2007
2007 Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS. 21:1373-1375. 2007
2007 Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry. Biomedical Chromatography. 21:410-414. 2007
2007 Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. Journal of Pharmacokinetics and Pharmacodynamics. 34:35-55. 2007
2007 Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. Journal of Clinical Pharmacology. 47:201-208. 2007
2006 Design issues in initial HIV-treatment trials: Focus on ACTG A5095. Antiviral Therapy. 11:751-760. 2006
2006 Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. Journal of the American Medical Association. 296:769-781. 2006
2006 Reply to Tong et al. [4]. Clinical Infectious Diseases. 43:542-544. 2006
2006 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: Using viral dynamic models that incorporate drug susceptibility and adherence. Journal of Pharmacokinetics and Pharmacodynamics. 33:399-419. 2006
2006 Tipranavir: A novel nonpeptidic protease inhibitor of HIV. Clinical Pharmacokinetics. 45:665-682. 2006
2006 Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy. Lancet Infectious Diseases. 6:215-225. 2006
2006 Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study. Clinical Infectious Diseases. 42:401-407. 2006
2006 Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 20:223-231. 2006
2006 Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood. HIV Clinical Trials. 7:263-269. 2006
2006 Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood.. HIV Clinical Trials. 7:263-269. 2006
2005 Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. ACP journal club. 143. 2005
2005 Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359 2005
2005 Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy. 10:375-392. 2005
2005 Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 19:1309-1315. 2005
2005 Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antiviral Therapy. 10:469-477. 2005
2005 Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS. 19:1059-1063. 2005
2005 Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance 2005
2005 Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 19:145-152. 2005
2005 Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: Pediatric AIDS Clinical Trials Group Protocol 403 2005
2004 Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS. 18:2391-2400. 2004
2004 Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals 2004
2004 Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clinical Trials. 5:288-293. 2004
2004 Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. Journal of Infectious Diseases. 190:886-893. 2004
2004 Pharmacokinetic enhancement of protease inhibitor therapy. Clinical Pharmacokinetics. 43:291-310. 2004
2004 Antiretroviral drug content in products from developing countries. Clinical Infectious Diseases. 38:1317-1319. 2004
2004 Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New England Journal of Medicine. 350:1850-1861. 2004
2004 Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS. 18:939-943. 2004
2004 Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359. Journal of Infectious Diseases. 189:1176-1184. 2004
2004 Detection of Nevirapine in Plasma Using Thin-Layer Chromatography 2004
2004 Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?. Antimicrobial Agents and Chemotherapy. 48:430-436. 2004
2004 Effects of Concentration and Temperature on the Stability of Nevirapine in Whole Blood and Serum 2004
2003 HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice. AIDS Research and Human Retroviruses. 19:1141-1150. 2003
2003 Duration of highly active antiretroviral therapy regimens. Clinical Infectious Diseases. 37:714-722. 2003
2003 Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1 [4] 2003
2003 Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS. 17:1659-1665. 2003
2003 Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1 2003
2003 Analysis of Generic Nevirapine Products in Developing Countries [7]. Journal of the American Medical Association. 289:2648-2649. 2003
2003 Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings 2003
2003 Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients 2003
2003 Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. 2003
2003 Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography 2003
2003 Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clinical Infectious Diseases. 36:373-377. 2003
2003 Therapeutic drug monitoring in the treatment of HIV-infection. Journal of Clinical Virology. 27:117-128. 2003
2002 Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antiviral Therapy. 7:267-270. 2002
2002 Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Research and Human Retroviruses. 18:909-916. 2002
2002 Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. Journal of Clinical Pharmacology. 42:1165-1170. 2002
2002 Durability of response to treatment among antiretroviral-experienced subjects: 48-Week results from AIDS Clinical Trials Group Protocol 359. Journal of Infectious Diseases. 186:626-633. 2002
2002 The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (aids clinical trials group study 850). Journal of Infectious Diseases. 186:198-204. 2002
2002 Pharmacokinetic enhancement of protease inhibitors 2002
2002 Antiretroviral pharmacokinetics in the paediatric population: A review. Clinical Pharmacokinetics. 41:1115-1133. 2002
2002 Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Research and Human Retroviruses. 18:825-834. 2002
2001 Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics. Antimicrobial Agents and Chemotherapy. 45:2771-2774. 2001
2001 Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios 2001
2001 Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial Agents and Chemotherapy. 45:236-242. 2001
2001 Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. HIV Clinical Trials. 2:193-199. 2001
2001 Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS clinical trials group protocol 373. Journal of Infectious Diseases. 183:715-721. 2001
2001 Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clinical Trials. 2:460-465. 2001
2000 Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases. 30. 2000
2000 Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS. 14:2869-2876. 2000
2000 Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 14:2495-2501. 2000
2000 Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370. AIDS. 14:1553-1561. 2000
2000 Long-term stability of nelfinavir mesylate in human plasma [5] 2000
2000 Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemotherapy and Pharmacology. 46:173-179. 2000
2000 Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359. Journal of Infectious Diseases. 182:1375-1384. 2000
1999 Indinavir concentrations and antiviral effect 1999
1999 Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). Clinical Pharmacology and Therapeutics. 65:161. 1999
1998 Potential confusion with antiretroviral drugs. American Journal of Health-System Pharmacy. 55:2639-2640. 1998
1998 Concentration-controlled zidovudine therapy. Clinical Pharmacology and Therapeutics. 64:331-338. 1998
1997 Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy 1997
1997 Valacyclovir. Annals of Pharmacotherapy. 31:185-191. 1997
1996 Clinical Pharmacokinetics of Zidovudine: An Update. Clinical Pharmacokinetics. 30:251-262. 1996
1996 Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [4]. Journal of Infectious Diseases. 174:673. 1996
1996 Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrobial Agents and Chemotherapy. 40:2721-2726. 1996
1996 Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [2]. ACP journal club. 124:855. 1996
1995 Antiretroviral drug interactions. International Journal of Antimicrobial Agents. 5:73-83. 1995
1995 Pentamidine Concentrations in a Mother with AIDS and in Her Neonate. Clinical Infectious Diseases. 20:1569-1570. 1995
1994 Agents for treating human immunodeficiency virus infection. American Journal of Health-System Pharmacy. 51. 1994
1994 Gender differences in human pharmacokinetics and pharmacodynamics. Journal of Adolescent Health. 15:619-629. 1994
1993 Advances in pharmacotherapy: treatment of HIV infection. Journal of Clinical Pharmacy and Therapeutics. 18:375-388. 1993
1993 Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma. Annals of Pharmacotherapy. 27:898-903. 1993
1988 Thromboxane synthesis and actions in isolated adrenergic nerve (pheochromocytoma-12) cells. Journal of Pharmacology and Experimental Therapeutics. 247:43-46. 1988
2017 Antivirals (Nonretrovirals) 2017
Principal Investigator On
(IMPAACT) Subcontract BRS-IPHRM-S-08-00056, Equipment awarded by SOCIAL & SCIENTIFIC SYSTEMS
A Multicenter, Open-Label, Noncomparative Study for the International Maternal, Pediatric, Adolescent AIDS Clinical Trials Group to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in HIV-1 Infected Children (Study) awarded by SOCIAL & SCIENTIFIC SYSTEMS
AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV awarded by Brigham and Women's Hospital
AIDS Clinical Trials Group (ACTG) awarded by University of California, Los Angeles
AIDS Clinical Trials Group Laboratory Center (ACTG) awarded by University of California, Los Angeles
AIDS Clinical Trials Group Network (ACTG) awarded by Brigham and Women's Hospital
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: Sp Lab A5324/A5345] awarded by University of California, Los Angeles
Aids Clinical Trial Group: ACTG awarded by Brigham and Women's Hospital
Anti-Viral Treatment in Mild Cognitive Impairment awarded by RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. - NEW
Antiretroviral Quantitation and Modeling in the Female Genital Tract awarded by Gates (Bill and Melinda) Foundation
IMPAACT 2019 - Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Disperible and Immediate Release Tablets in HIV-1-Infected Children less than 12 years of Age awarded by Johns Hopkins University
IMPAACT 2023 –A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 awarded by Johns Hopkins University
IMPAACT Network Lab PF Project Specific Task Order - Lab 12 (P1115) awarded by Johns Hopkins University
International Maternal Medicine Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership (P1066) awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1093) awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) Group Leadership (P1110) awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group awarded by University of California, Los Angeles
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1097 and P1101) awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group - P1097A LAB 05 awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials Group ("IMPAACT") awarded by SOCIAL & SCIENTIFIC SYSTEMS
International Maternal Pediatric Adolescent AIDS Clinical Trials Group -- Lab 11 awarded by Johns Hopkins University
International Maternal Pediatric Adolescent AIDS Clinical Trials Group Leadership (ARRA Administrative Supplement) awarded by SOCIAL & SCIENTIFIC SYSTEMS
International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network (IMPAACT LC) awarded by University of California, Los Angeles
Laboratory Center - IMPAACT Leadership Group awarded by Childrens Hospital Los Angeles
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ awarded by University of California, Los Angeles
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ [Specialty Lab Fixed Rate] awarded by University of California, Los Angeles
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/[PF Spec. Lab] awarded by University of California, Los Angeles
Long Acting Self Administered HIV Therapy with CCR5 Antibody PRO 140 awarded by Drexel University College of Medicine
Predictors of Treatment Toxicity, Failure, and Relapse in HIV-related Tuberculosis awarded by VANDERBILT UNIVERSITY
Private Grant awarded by ACTUACTED MEDICAL INC
Private Grant awarded by VIIV HEALTHCARE COMPANY
UAB ACTG Pharmacology Support Laboratory awarded by SOCIAL & SCIENTIFIC SYSTEMS
UAB IMPAACT Pharmacology Support Laboratory awarded by SOCIAL & SCIENTIFIC SYSTEMS
A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer awarded by Komen (Susan G.) Breast Cancer Foundation
A Phase II, Single-Stage, Single Arm Investigation of Oral Valganciclovir Therapy in Infants with Asymptomatic Congenital Cytomegalovirus Infection awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-Topic) awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC) awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
Elexacaftor/Tezacaftor/Ivacaftor after Lung Transplant awarded by UNIVERSITY OF WASHINGTON
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
Small Molecule Inhibitors Targeting Adenovirus awarded by University of Southern California
Doctor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, University of Minnesota System : Twin Cities 1992
Edward Acosta


text:
Barack Obama: Muslim elders too 'boring' to win Isil propaganda war
Islam is not to blame for rise of Islamic State says Barack Obama, arguing people not religion responsible for violence and terrorism
President Barack Obama speaks at the White House Photo: EPA
11:27PM GMT 18 Feb 2015
President Barack Obama has warned that Muslim community leaders are in danger of losing the propaganda war with the Islamic State in Iraq and the Levant (Isil) and are often too "boring" to prevent their young people from getting radicalised.
Paying Isil a back-handed compliment for the effectiveness of its gruesome social media outreach campaign, Mr Obama said it was imperative to reach young Muslims and address their social, political and economic grievances in a way that they understood.
"By the way, [to] the older people here - as wise and respected as you may be - your stuff is often boring," he told a White House summit on combatting the rise of extremism, "compared to what they're doing. You're not connected. And as a consequence, you are not connecting."
Mr Obama said it was time to be "honest" that slickly-produced Isil videos of fighting scenes, beheadings other atrocities were succeeding in brainwashing young Muslims.
"That's the truth. The high-quality videos, the online magazines, the use of social media, terrorists Twitter accounts - it's all designed to target today's young people online in cyberspace."
Islamic State 'planning to use Libya as gateway to Europe'
The Middle East is red with the blood of Christians
Italy warns Islamic State is allying with Libyan Islamist groups
Libya's descent into chaos at the hands of Isil proves that sometimes there are no solutions
'Islamic State's ambitions in Libya are a direct threat to Europe'
'Monstrosity' of Isil in Libya must be defeated, warn Western leaders
His remarks came amid mounting criticism from some hawks in Washington that Mr Obama has refused to directly link Isil's extremism with the religion of Islam.
However Mr Obama said that he rejected that linkage because it legitimised the Islamic State's own propaganda that they are fighting a holy war against the West.
"We must never accept the premise that they put forward, because it is a lie," Mr Obama said, "nor should we grant these terrorists the religious legitimacy that they seek. They are not religious leaders; they're terrorists. We are not at war with Islam."
Outlining a three-pronged strategy to reduce the radicalisation process that has seen more than 500 British Muslims alone go to Syria and Iraq for Jihad, Mr Obama warned of a long war ahead for the hearts and minds of young Muslims that would not be
"Given the complexities of the challenge and the nature of the enemy, which is not a traditional army, this work takes time and will require vigilance and resilience and perspective," he said, "But I'm confident that just as we have for more than two centuries, we will ultimately prevail."
Barack Obama on extremism: 'terrorists are targeting young people through Twitter'
Middle East »
Syria »
Peter Foster »

redpajama_set_name: RedPajamaCommonCrawl


The Petface ball launcher is ideal for most dogs or other animals that love chasing balls. The launcher makes repeatedly throwing the ball less of a chore and reduces the need to bend over to pick up the ball once returned. made with a sturdy plastic the launcher should last for many hours of play. The launcher includes one ball and extra balls are available, sold separately.


text:
CLS Book Recommendations
We often get requests from our members and friends for book recommendation. We concede that this is not an exhaustive list, and also did not want it to extend past 25 books, but wanted to have some great recommendations. You can find most of these books online. We suggest, in an effort to support local Christian bookstores, that you order these from Hearts and Minds Books, which runs our conference bookstore every year.
We are pleased to promote, first and foremost, what we view as the best book on Christian calling and the legal profession:
Redeeming Law, Michael P. Schutt, IVP Academic, (2007)
Biblical Calling/Vocation
Can a Good Christian Be a Good Lawyer, Thomas E. Baker and Timothy W. Floyd, eds., (South Bend, IN: University of Notre Dame Press, 1997)
How Then Should We Work? Rediscovering the Biblical Doctrine of Work, Hugh Whelchel, Institute for Faith, Work & Economics, The (May 16, 2012)
Jesus in the Courtroom: How Believers Can Engage the Legal System for the Good of His World, John Mauck, Moody Publishers (July 4, 2017)
The Lawyer's Calling: Christian Faith and Legal Practice, Joseph Allegretti, (Mahwah, NJ: Paulist Press, 1996).
In His Chambers: A Ninety-One Day Devotional Experience for Lawyers, Eric Mounts (Bloomington, IN: Westbow Press);
What Does the Lord Require of You? Devotional Readings for Lawyers, Lynn R. Buzzard, ed., (Beaver Falls, PA: Geneva School of Law, 1997).
Christianity on Trial, W. Mark Lanier, IVP Books (June 23, 2014)
Christian Living (Lawyers)
Divine Collision: An African Boy, an American Lawyer, and Their Remarkable Battle for Freedom, Jim Gash, Worthy Publishing (January 26, 2016)
The Good News About Injustice: A Witness of Courage in a Hurting World, Gary Haugan, IVP Books; 10th Anniversary ed. edition (October 8, 2009)
The Peacemaker: A Blblical Guide to Resolving Conflict, Ken Sande, Baker Books; 3 edition (January 1, 2004)
The Intersection of Faith and Law
A Higher Law: Readings on the Influence of Christian Thought in Anglo-American Law, Jeffrey A. Brauch, ed., (Buffalo, NY: William S. Hein & Co., 2d ed. 2008)
Christian Perspectives on Legal Thought, Michael McConnell, Robert Cochran, and Angela Carmella, eds., (New Haven, CT: Yale University Press, 2001)
Christianity and Law, Stephen C. Perks, (Kuyper Foundation, 1993)
Faith & Law, Bob Cochran, NYU Press (December 1, 2007)
Faith & Order: The Reconciliation of Law and Religion, Harold Berman, Wm. B. Eerdmans Publishing Co., (January 1, 1993)
Law and the Bible: Justice, Mercy and Legal Institutions, Robert F. Cochran Jr., David VanDrunen, eds., IVP Academic (October 13, 2013)
Law and Revolution, Harold Berman, Harvard University Press; Reprint edition (December 7, 1983)
Western Creed, Western Identity: Essays in Legal and Social Philosophy, Jude P. Dougherty, (The Catholic University Press, 2000)
Recovering Self-Evident Truths: Catholic Perspectives on American Law, Michael A. Scaperlanda and Teresa Stanton Collett, eds., (Washington, DC: Catholic University of America, 2007)
The Theological Foundation of Law, Jacques Ellul, (New York: Seabury Press, 1969)
A Covenant to Keep: Meditations on the Biblical Theme of Justice, James Skillen, (Washington, DC: Center for Public Justice, 2000)
God's Joust, God's Justice: Law and Religiion in the Western Tradition, John Witte, Eerdmans (October 31, 2006)
God, Justice, and Society: Aspects of Law and Legality in the Bible, Jonathan Burnside, (Oxford, UK: Oxford University Press, 2010)
Justice: Rights and Wrongs, Nicholas Wolterstorff, (Princeton, NJ: Princeton University Press, 2010)
Just Mercy: A Story of Justice and Redemption, Bryan Stevenson, (New York: Spiegel and Grau, 2014)
Law and the Bible: Justice, Mercy and Legal Institutions, Robert Cochran and David VanDrunen, eds., (Downer's Grove, IL: InterVarsity Press, 2013)
The New Jim Crow: Mass Incarceration in the Age of Colorblindness, M. Alexander, (New York: The New Press, 2012)
General Scholarship
City of God, Augustine
Treatise on Law, Thomas Aquinas
Letter from a Birmingham Jail, Martin Luther King, Jr.
The Roots of American Order, Russell Kirk, (Wilmington, DE: Intercollegiate Studies Institute, 4th edition, 2003)
Rediscovering the Natural Law in Reformed Theological Ethics, Stephen J. Grabill, (Grand Rapids, MI: Eerdmans, 2006


Hofa Decor Sdn Bhd is an industry leader in providing exclusive and customised services to all our customers for their decorating needs. We strive to create a successful working partnerships throughout the construction process. It is our aim to provide the best quality finishings, workmanship, commitment and after sales service to all our projects.
Our pledge to our customers is to establish long lasting relationships by exceeding their expectations and gaining their trust through exceptional performances.


Is the idea of looking nerdy in futuristic glasses keeping you from embracing Google Glass? Fret no further. According to MIT Technology Review, a team of researchers from mostly Korean institutes, including Samsung, have made a breakthrough on a less conspicuous intelligent eyewear solution – electronic contact lenses.
The team has tested their prototypes on rabbits – since their eyes are about the same size as ours – and found no negative effects after five hours of use. A light-emitting diode, or LED, was mounted on store-bought soft contact lenses using a transparent, stretchy conductor that they developed.
Of course, electronic contact lenses have been around for some time now. Sensimed, a Swiss producer of micro-systems for medical devices, offers contact lenses that monitor pressure fluctuation in the eyes for glaucoma treatment. Google Glass project founder Babak Parviz and other researchers also have managed to develop contact lens displays.
The difference is that those lenses are rigid or non-transparent, making for an uncomfortable experience. Although still in its infancy, the Korean team's conductor may become a necessary component in developing comfortable electronic contact lenses in future.


text:
Biggest Tech Innovations in Malaysia
Casino/Betting
Rupali Gupta
The Malaysian Minister of Science, Technology, and Innovation said recently that the agency welcomed the country's Prime Minister's announcement at the opening of Invest Malaysia 2021 recently that Malaysia will become a high-technology country by 2030. The goal is to build an economy that is driven by science, technology, and innovation. This will help the development of technology in the local area by giving people jobs and economic opportunities in artificial intelligence, the Internet of Things, and blockchain technology.
Another thing that the Minister said was that the agency is working on 17 technology roadmaps, including one for artificial intelligence, another for blockchain, another for electrical and electronics, another for advanced materials, robotics, and vaccines. These roadmaps are in line with the 10 science and technology drivers and 10 socioeconomic drivers that are in the 10-10 Malaysia science, technology, and innovation and economic frameworks, which you can read more about here (10-10 MySTIE).
MOSTI wanted to make Malaysia a vaccine producer, generate RM600 billion in potential trade returns in the electric and electronics sector by 2025, make a big impact on GDP through the identified fields, and make 5,000 start-ups by 2025.
In the past, Malaysia and Northern England had a lot of good things to say about each other.
Malaysia is on its way to becoming a major player in the world.
A lot of people in Malaysia are interested in tech.
Land-based and online gambling is banned in Malaysia because it is a mostly Muslim country. Offshore betting sites can still be accessed safely and securely. Unlike in other countries in the region, gambling is not punished with a prison sentence. It's important to choose a safe platform, and we found a source that had a lot of useful information about online sports betting in Malaysia along with the best betting sites for Malaysian people. At the same time, betting is one of the most profitable things you can do online.
See also Let's find out more about the history of the online casino bonus
It's always been seen as morally wrong to play, or gamble, in countries and states all over the world. If you want to play a lot of different games, you should go to a web-based casino. How about that? All of the doubts have been put to rest, and it looks like it will have a long and prosperous life. Gambling has become very popular in Malaysia. Despite this, it has a big effect on the economy. If you want to start gambling and make a lot of money, you need to think about the facts.
Malaysia is a member of the British Commonwealth. It is the UK's second-biggest trading partner in Asia, after China. The two countries signed a Memorandum of Understanding in 2016 to keep their trade relationship strong. Sure enough, the DIT has helped more than 20 collaborations and investments between UK companies and more than $131 million worth of trade by UK tech companies in Malaysia since that year. The best part about this? After Brexit and the coronavirus pandemic, there are no signs that this collaborative spirit is going away.
Government initiatives make it easier for people to work together. Not only does the Malaysian government help businesses with tax incentives, but there is also a One-Stop Centre for Business Travellers. This project was organized by the Malaysian Investment Development Authority. It makes it easier for international business travelers to move around the country.
CEO WORLD Magazine said that Malaysia was the best country to invest in or start a business in. It looks like a lot of people have the same good things to say. There was a ranking of countries based on how well they were at being innovative. The World Bank said it was the second easiest country to do business in. Similar groups think Kuala Lumpur, the capital of Malaysia, has a great environment for new businesses to grow. So, why not join in the fun?
See also Serie A - Best Sites To Check Live Scores
Malaysia's digital economy now makes up 19.1% of the country's GDP. It is also hoped that over the next few years, this figure will rise to 22.6 percent. This is proof that the government wants to keep the tech industry growing. Farming has become more modern because of the rise of "agri-tech," which uses AI and data analysis to make farming easier. Health technology has made a lot of progress, too.
As far as who you want to reach with your website content, the high use of technology allows you to reach people from all over the world. Because 99 percent of people have smartphones and 86 percent are on social media, this means that a lot of people use them. The fact that big tech companies like Google, Microsoft, and Huawei have recently set up shop there might be interesting to learn about. If you want to be a digital person, Malaysia looks like the place to be.
Rupali Gupta is a blogger and professional writer who loves to write about technology and entertainment. Techzimo is one of her successful websites filled with great tech news, Know more about her on Youtube Facebook Twitter Linkedin Instagram


In this digital era, OOH becomes the last window of influence for shoppers. That is just before people shop. It has been proven that customers made a purchase from the physical store after seeing the billboard ad.
OOH advert near urban shopping centres such as malls and supermarkets creates an environment where people get highly influenced. Placing OOH near strategic locations improves the effectiveness of OOH advert. They drive customers directly to the store.
Especially in case of FMCG products, OOH works brilliantly. Even for other products and services, OOH placed at the right place and at the right time is highly effective. Ex. Real estate industry grabs high attention through OOH marketing.
Here, location becomes a prominent factor in outdoor advertisements. People want to see information related to their location.
However, in this digital age, the online shopping is growing rapidly. So what role OOH is playing in this online environment? OOH directly influences the product search. Not only offline but it can fetch you great sales on your online store too!
OOH is a powerful media tool to create a distinct identity of your brand as they come into interaction with your audience in their free time, while they are transiting.
OOH advertisements are a highly effective way to drive traffic in-store traffic. Be more targeted with your location. Collect the relevant data and use your industry information to drive in-store promotions.
To drive direct traffic to your brick n mortar store, give customers something which they don't/can't get online. OOH is not only about displaying products or services and driving customers to purchase them. It is about building a distinct identity in the customers' mind about your brand.
Global advertisers is working closely with developing new possibilities in OOH media planning. Do you have a retail store? Please share your story with us in the comment section below on how you are driving direct traffic to your store.
Share the post "How OOH is driving customers to store"


Join CardFlight at Western States Acquirers Association (WSAA) 2018 Conference 2018 WSAA Conference September 12-13, 2018 Hyatt Regency Scottsdale Resort and Spa at Gainey Ranch, Scottsdale, AZ We will be at the show floor at Booth #6 demonstrating our SwipeSimple products and showing you how you can provide advanced payment acceptance technology to your merchants.
Fintech companies met Apple Inc.'s Sept. 7, 2016, launch of the iPhone 7 series with an array of market-ready solutions. Many had anticipated the company's decision to eliminate the iPhone's audio jack. Apple's move ‒ hailed as "courageous" by the company and widely panned by consumers and merchants who rely on audio jack access for their ear buds and payment card reading peripherals ‒ spawned an immediate array of aftermarket solutions.
BluePay is proud to announce the availability of EMV mobile processing using CardFlight's point-of-sale solution, SwipeSimple.
CardFlight Releases the Latest Trends on EMV Chip Card Usage in the U.S.
With an eye to easing the integration of EMV payment acceptance in mobile apps used for card-present transactions, mobile point-of-sale provider CardFlight now offers integration with Stripe, a payments provider specializing in online transactions.
CardFlight, a mobile point of sale (POS) technology provider, today announced a new integration with Stripe to empower developers to accept EMV chip card payments from within their own mobile applications. As part of the integration, CardFlight will make available mobile card readers that support EMV chip card and swiped magnetic stripe payments to Stripe merchants and developers.
Having extensive experience studying FinTech industry and expertise in various sectors, the LTP team has been actively following some of the top innovators to be up-to-date with the latest solutions and outstanding products existing in the market. New FinTech startups are being discovered every day and competition for the top positions has been tightening up. We have been putting together lists of the most promising and most innovative FinTech startups across sectors, geographical regions, industries. There are always certain companies that we found to be among the hottest ones across both LTP and external rankings.
Cayan, The Payment Possibilities Company™, and CardFlight, a top mobile point of sale (POS) technology provider, today announced an agreement to offer EMV-ready mobile payment acceptance solutions to Cayan partners and merchants. As part of the partnership, Cayan will offer CardFlight's SwipeSimple product as its preferred mobile POS solution for merchants looking to accept credit and chip card payments from smartphones and tablets.
In a round led by Dan Henry and MATH Venture Partners, mobile card payment solutions provider, CardFlight has raised $4.2 million in Series A investment. Founder and CEO Derek Webster called the funding a validation of his company's leadership role in the mobile payments space. He added that the capital would help the company build its engineering team and speed up deployment of CardFlight's EMV-enabled payment-acceptance technology in the United States.
Mobile point-of-sale technology maker CardFlight has announced $4.2 million in new Series A funding.
CardFlight, a leader in mobile point of sale (POS) technology, announced today that it has raised $4.2 million in Series A funding. The round was co-led by an investor group assembled by Dan Henry and MATH Venture Partners.
CardFlight, a leader in mobile point of sale (POS) technology announced that its suite of mobile solutions has been certified by First Data, a global leader in commerce-enabling technology and solutions, to accept EMV "chip card" payments. This will enable merchants to accept EMV payments on iOS and Android devices ahead of the October 1 liability shift.
Payment Alliance International (PAI), a leader in electronic payment processing solutions, and CardFlight, a top mobile point of sale (POS) technology provider, today jointly announced they have entered into a partnership agreement for EMV mobile POS (mPOS). PAI will offer CardFlight's EMV mPOS acceptance solutions to its market partner distribution network and merchant customers nationwide.
CardFlight, a leader in mobile point of sale (POS) technology announced today the availability of EMV-ready chip card readers for its SwipeSimple mobile point of sale solution.The United States is in the process of migrating to the EMV chip card standard, with a liability shift occurring in October 2015 that provides incentives for merchants to upgrade their payment terminals to devices capable of reading chip cards.
CardFlight, a leader in mobile point of sale (POS) technology is announcing that it has partnered with Integrity Payment Systems, a leading payment service provider, to offer CardFlight's mobile POS solutions to Integrity's merchants and partners.
CardFlight, a leader in mobile point of sale (POS) technology, is excited to announce it has partnered with Merchants' Choice Payment Solutions (MCPS), a merchant services provider, to provide a custom mobile POS solution to merchants through its sponsor bank's network of retail branches.
CardFlight, a leader in mobile point of sale (POS) technology, and Anovia Payments, a leading payment service provider, are announcing an agreement to provide customized mobile payment solutions to Anovia's VARs, partners and merchants.
Provider of mobile POS technology will allow merchants to login to SwipeSimple application via fingerprint.
CardFlight has won the 2014 Technology Innovation Award from the Electronic Transactions Association (ETA), the global trade association representing companies that offer electronic transaction processing products and services. The Technology Innovation Award is presented annually to one company that makes significant advancements for the industry and has demonstrated results with a product that is currently available in the marketplace.
CardFlight, the leading provider of mobile point of sale (POS) technology, announced at TRANSACT 14 in Las Vegas, NV today the launch of SwipeSimple, a turn-key solution that empowers credit card processors, merchant service providers, ISOs, agents and other resellers to offer a mobile POS product to their merchants.


The "About Us" button and "Before you Order" link provide pricing and payment policies as well as downloads of software manuals. Be sure to check the Updates link (bottom of page) for the latest free updates to MPO software.
Generate ephemerides and/or finder charts for any asteroid in the MPC or Lowell databases as well as user-defined elements.
Daily calendar shows asteroid appulses with other asteroids, DSOs, and bright stars.
Opposition listings for current year for numbered asteroids show you which asteroids are "ready for prime-time".
Opposition data for the period from 1995 – 2050 can be generated on-the-fly for any asteroid, numbered or un-numbered.
The electronic download consists of a "starter" DVD±R dual-layer ISO image (1)(2) and includes the MPOSC3, APASS (DR-9, MPO format), and CMC-15 (MPO format). The program also supports UCAC4 (native format). The UCAC4 catalog is available as 2 DVD±R dual-layer ISO images for free download(1)(2). Download instructions will be provided via email after receiving your order.
(1) The ISO images must be burned to the approriate type of DVD disc before using. Software can also be used to "mount" the ISO images a drive on your computer. There are many programs available, one being Daemon Tools Lite, which is free (with advertising) or $5.99 for a no-advertising licence for 3 PCs. Windows 10 may not require the additional software and will see the ISO images a drive automatically. This must be confirmed before you decide whether or not to purchase image mounting software.
(2) Connection and data rates may apply.
The starter DVD is used to install all MPO programs. You will be provided with the necessary release code(s) to install only those products that you purchase.


text:
Ukraine Lessons for Israel! Biden Makes Anti-American Nations Great Again!
by Tim Buck | Mar 25, 2022 | America, Isreal, Joe Biden, Nations, Tim's Articles, Turkey, Ukraine | 0 comments
Ukraine's Lessons For Israel
By Caroline Glick
Edited by Tim Buck
In the months and weeks that led up to Russia's Feb. 24 invasion of Ukraine, Western powers signaled clearly that they were prepared to accept the disappearance of Ukraine as an independent state.
U.S. President Joe Biden virtually invited Russian President Vladimir Putin to invade in late January when he said that a "minor incursion" would leave NATO flat-footed. German Chancellor Olaf Scholz, like his predecessor Angela Merkel, served as the Kremlin's unofficial spokesman in Europe.
But once Russian forces invaded, the West's plans to yell a bit and look away went awry. The Ukrainians failed to play their assigned role of Paschal lambs. Instead, they rallied around their flag and their president, Volodymyr Zelensky.
For his part, Zelensky captivated the hero-starved West. His rejoinder, when the Biden administration offered to evacuate him from Ukraine on the second day of the war, "I don't need a ride, I need ammunition," reminded Americans of a time when they weren't being attacked for being transphobic or systemically racist, a time when patriotism was permitted.
Once Americans and other Western audiences got a whiff of Ukrainian nationalism, it became politically impossible for Washington, Brussels, Berlin, Paris and London to turn their backs on Kyiv. And so, with little deliberation, Biden and his European counterparts announced a series of unprecedented financial and economic
sanctions on Russia and massive shipments of arms and humanitarian aid to Ukraine.
For a moment, it was possible to wonder whether Russia's reminder that the problems of the world cannot be reduced to the pronouns one uses or the amount of carbon one burns on an average day would change the focus of Western elites. But it was not to be. The ruling classes in Brussels and Washington made clear that the war in Ukraine would not steer them off course.
While Poland is giving refuge to nearly two-thirds of the 3 million Ukrainians who have fled their homes, and Hungary has taken in 10% of them, the E.U. parliament passed economic sanctions against both nations last week. Their crime? The nationalist governments in Warsaw and Budapest refuse to toe Brussels' line on Muslim immigration and LGBTQ indoctrination.
As for the Biden administration, Ukraine's fight for national survival in the face of Russian aggression is all well and good. But appeasing Iran is the Biden administration's top priority. And Biden can't appease Iran without Russia. So to keep Russia on board with his administration's efforts to close a deal with Iran, Biden agreed to cut Russia's lucrative business with Iran out of the sanctions.
Russia can expect to receive $10 billion developing Iran's nuclear installations and billions more in arms sales. The implications for Ukraine are clear: The US is willing to let them fight the Russians, but will not help the Ukrainians defeat Russia, because the United States cares more about empowering Iran than helping Ukraine survive.
The deal that Biden is concluding with Iran is itself a stunning testament to the radicalism of the Biden team and its refusal to let reality interfere with its policies. It will provide Iran with $90 billion from sanctions relief. That astronomical sum guarantees massive cash infusions into the coffers of Iran's in-house global terrorist organization–the Islamic Revolutionary Guards Corps, which Biden is set to remove from the State Department's list of foreign terrorist organizations–and to Iran's terror armies in Lebanon, Yemen, Iraq, Syria and the Gaza Strip.
Iran will have the funds to expand its missile and drone capabilities. And thanks to the lax restrictions it will face on its nuclear operations, it will become a nuclear threshold state by 2025 at the latest.
Although the West's progressive agenda necessarily limits the support it is willing to provide Ukraine, the West's ruling classes need to placate their publics, who admire Ukraine, compelling them to provide significant if not determinative military, humanitarian and political assistance to Kyiv. And given Ukraine's willingness to fight it out with Russia, that support may be sufficient to enable Ukraine to withstand Russia's assault for long enough to maintain its independence.
The widespread assessment today is that the Ukrainians will be able to continue fighting, despite Russia's clear military superiority, for another month or six weeks. Given the high losses the Ukrainians are inflicting on the Russians, and assuming that the Russians begin to feel the full impact of the economic and financial sanctions within the next two to three weeks, it is possible that by mid-April, the Ukrainians will be able to negotiate ceasefire terms with Russia that will leave the country independent and more or less intact.
There is a moral to this story for Israel.
Ukrainians can still hope for and expect a future of freedom and independence because they have refused to bow before either Russia or to the West.
If Israel were paying attention to the dynamics at work in the West's behavior towards Ukraine, it would be adopting policies opposite to those it is currently pursuing, both in relation to Ukraine and Russia and in relation to the West.
Unlike Zelensky, who hasn't hesitated to call the United States and Germany out for their fence-sitting, the Bennett-Lapid-Gantz government has subordinated all Israeli policies to the Biden administration's agenda.
If Israel were putting its own interests first, as Zelensky has, Prime Minister Naftali Bennett wouldn't be trying to mediate between Zelensky and Putin. Instead, Israel would make do with a simple but clear message: Israel supports Ukraine's sovereign independence and territorial integrity and calls on Russia to end its offensive operations.
Israel ought not and need not go beyond that statement.
The reasons for this are obvious. This is not Israel's war, and words have consequences. Israel cannot mediate this conflict because it has no leverage over either actor to persuade them to compromise.
As for the significance of words, in order to succeed, a mediator has to be perceived by both sides as someone who accepts the basic legitimacy of their positions. But as a threatened democracy, it is a dangerous proposition for Israel to accept Russia's view that Ukraine has no right to exist as an independent and distinct nation-state.
When the next round of "mediation" between Israel and the Palestinians begins, how will Israel be able to demand that any prospective mediator reject out of hand the Palestinians' position that the Jewish state has no right to exist?
This brings us to the second policy Israel should be adopting in the face of the war in Ukraine. Israel should be devoting all of its efforts on the ground to rapidly facilitating the mass aliyah of Ukrainian Jewry. As it stands, there are 10,000 Ukrainian Jews waiting to make aliyah.
Instead of processing their applications, the Foreign Ministry is giving them appointments at consulates and embassies in Warsaw, Budapest and Bucharest three and six months from now and filling planes with non-Jews instead. Non-Jewish Ukrainians, it bears noting, have no problem resettling in the countries bordering Ukraine and throughout Europe. Yet, as 10,000 Ukrainian Jews are forced to wait for months to come to Israel, 10,000 non-Jewish Ukrainians have been airlifted to Israel.
This brings us to Israel's real problems–Iran, the Palestinians and the Biden administration.
Zelensky's fierce defense of his country, and the Ukrainian people's refusal to stand down in the face of Russia's advance, have compelled the Biden administration to support Ukraine even at the risk of a world war because the Ukrainians are standing for the values of freedom and independence that the United States is supposed to personify on the world stage.
If Israel were to take a page from Ukraine's playbook, its leaders would be attacking the immorality of the Biden administration's capitulation to Iran's demands in the appeasement talks in Vienna.
The Bennett-Lapid-Gantz government's silence in the face of Biden's abdication of moral and strategic leadership in the Middle East undermines the efforts of Israel's supporters in Congress and the international community. The Republicans, for instance, are compelled to explain why they are more opposed to Biden's capitulation to Iran than the Israeli government is.
Then there are Israel's Arab partners. The Saudis and the Emiratis have been more outspoken in their opposition to Biden's Iran policies than Israel. The Arab leaders in the Gulf look at the silent, supine Israeli government in astonishment and distrust. The strategic consequences are already tangible. Rather than redouble their cooperation with Jerusalem, the Saudis and the Emiratis are setting their sights on Moscow and Beijing.
The situation with the Palestinians is also disturbing, and speaks clearly to the destructive implications of Bennett's decision to play mediator between Russia and Ukraine.
Two weeks ago, Congress passed an omnibus spending bill, which Biden signed. With AIPAC's support, the bill contained a section on Israel that significantly downgraded the U.S. commitment to the Jewish state.
The section on Israel was an amended version of a law that passed initially in 2012, and required the United States to "assist" and "support the Government of Israel" in its ongoing talks with the Palestinians. The new law deleted the part about supporting Israel. Under the new law, the United States is obligated to support "a negotiated solution to the Israeli-Palestinian conflict resulting in two states living side by side in peace, security, and mutual recognition."
In other words, under the amended law, the United States is committed to supporting the establishment of a Palestinian state, whether Israel supports it or not.
Sen. Ted Cruz has fought since last July to block the passage of this amendment because he recognized the damage it was liable to do both to U.S.-Israel ties and to Israel's national security. The Israeli Embassy, on the other hand, was less concerned.
Senate sources explain that Israel's diplomats were nowhere to be found as Cruz fought adoption of the amendment.
The worst aspect of the amended law is that it wasn't initiated by the usual anti-Israel forces in the so-called "Squad." AIPAC supported the amendment, and so did mainstream Republican senators, like the ranking Republican on the Senate Foreign Affairs Committee, James Risch, and Sen. Rob Portman.
The implications are clear. When Israel opts to remain silent as its interests and position are undermined, not only does it strengthen its enemies, it loses its friends.
After Russia invaded Ukraine, many Ukrainians told Israeli reporters on the scene that they were inspired by Israel, which has always fought its own battles and survived even in the face of global indifference and hostility. Today, the opposite should be the case.
Israel's government must learn from the Ukrainians. The West will not fight for a threatened democracy. States that wait for green lights from the West to defend themselves will not survive. But states that defend themselves will see sufficient forces rally to their side to enable them to persevere and survive.
A view of Eclipse, a luxury yacht belonging to Russian businessman Roman Abramovich, recently docked at a port in the resort of Marmaris, Turkey. (IHA via AP)
Russian Oligarch Yacht
Parked in Turkey
A Russian pair of yachts belonging to Chelsea soccer club owner and sanctioned Russian oligarch Roman Abramovich have docked at resorts in Turkey, according to the Associated Press.
Turkey has not imposed economic sanctions on Russia over its invasion of Ukraine last month, nor has it frozen assets belonging to top Russian businessmen linked to Russian President Vladimir Putin.
The private DHA news agency said Tuesday the Bermuda-registered Eclipse docked in the resort of Marmaris.
A day earlier, Abramovich's Bermuda-flagged luxury yacht My Solaris arrived in the nearby resort of Bodrum, triggering a protest by a group of Ukrainians who boarded a small motorboat and tried to prevent the yacht from docking.
NATO member Turkey has close ties to both Russia and Ukraine. It has criticized Moscow's invasion of Ukraine but has also positioned itself as a neutral party trying to mediate between the two.


All fourteen items in the above $50K high estimate range in the recent single owner collection sale at Phillips found buyers, and when momentum like that builds up, the rest of the sale usually takes care of itself. With an overall Buy-In rate under 30% and plenty of positive surprises to push the numbers higher, the Total Sale Proceeds came in just above the middle of the aggregate pre-sale estimate.
The top lot by High estimate was lot 21, Richard Avedon, Marilyn Monroe, New York City, May 6, 1957, estimated at $200000-300000; it was also the top outcome of the sale at $250000 (image above via Phillips).


text:
Pulitzer Prize winning photographer visits CCCC
Pulitzer Prize winning photographer Jose Galvez speaks with a Central Carolina Community College student ... (more)
05.03.2016 • College & Community • College General
SANFORD - Pulitzer Prize winning photographer Jose Galvez gave students a peek behind his lens and into his experience during a lecture and exhibition on April 22 at Central Carolina Community College in Sanford.
Renowned for his black-and-white images documenting Latino life in the United States, Galvez stood in front of a screen projecting his work while describing his own journey from a shoeshine boy growing up in a Mexican American household in Tucson to staff photographer at the Los Angeles Times, where he was part of a team that received the Pulitzer for a series on Latino life in southern California. Along the journey, he discussed topics ranging from immigration to the art of photography.
It was a mixture of humorous and poignant stories that began with one of the first he covered in North Carolina: the experience of a farmer in West Jefferson who crossed illegally into Texas as a teenager to work. After receiving amnesty in the late 1980s and moving to the Blue Ridge Mountains to work with Christmas trees, he became manager of the migrant workers and established his own growing operation.
"Jorge works for a large tree farmer, but he's also his own boss," Galvez told the students as photos from the tree farm faded in and out behind the narrator. "He spent the last couple of decades learning the business. He invested in his own lots and trees. In some cases, he owns the land; in others, just trees .... He hopes one day to have his tree in the White House."
As remarkable as that story was, Galvez's own story is even more inspiring.
Describing himself as "a natural born hustler" early in life, Galvez recounted how he sold newspapers, collected boxes to exchange for cookies and even shined shoes after his father made him a shoeshine box, something that might not have seemed all that consequential at first. But when a reporter for the Arizona Daily Star called him upstairs one night for a shine, the 10-year-old saw his future.
"There was an energy and electricity in the room that was exciting to watch," Galvez recalled. "It hit me right there on the spot that I wanted to belong to this room. I wanted to make it my new home. Instead of selling papers, I wanted to be part of making it."
For years, Galvez made himself useful in the newsroom - shining shoes, running errands and studying the reporters, who became his mentors. He bought his first camera in a pawn shop during high school, went on to major in journalism at the University of Arizona and dove head first into his new career.
"That shoeshine box changed my life," he said.
Before the lecture, students walked through a small gallery of Galvez's photography -- an exhibition on Cesar Chavez, a farm worker and social activist whom the late Sen. Robert F. Kennedy described as "one of the heroic figures of our time." Chavez, who died 23 years ago, co-founded the National Farm Workers Association to improve working conditions for field workers and received a number of honors for promoting civil rights.
Galvez said he chose this portion of his extensive portfolio to celebrate National Farmworker Awareness Week, a commemoration held each spring to highlight issues confronting farm workers in the United States. "I take this time to remember Cesar's contribution," Galvez explained. "There are real issues still for farm workers in the U.S. that need to be remembered and not forgotten."
After Galvez's formal presentation, students asked questions. Why does he shoot only with black and white film? It focuses his work and forces him to make every image count. And why, with Latino culture being such a large part of the national identity, does he think some contemporary politicians seem to be attacking it? That was one that made the photographer pause before giving his perspective on how changing demographics and fear can drive political sentiment.
Then there was another question: After experiencing such acclaim documenting the Latino experience, has he ever been tempted to branch out into other subjects? "No," Galvez said, shaking his head. "This has always been my calling."
For more information on Central Carolina Community College, visit the website at www.cccc.edu.


Dr. Helen Kaporis is a board-certified dermatologist who specializes in medical, surgical and cosmetic dermatology. Born and raised in New York City, Dr. Kaporis graduated with honors from Fordham University with a Bachelor of Science in Biology. She earned her medical degree at New York College of Osteopathic Medicine.
While in medical school, Dr. Kaporis completed a research fellowship in Cutaneous Oncology at Rockefeller University's Department of Investigative Dermatology. She has authored numerous publications in peer-reviewed journals, including Journal for Investigative Dermatology and Dermatologic Surgery. After medical school, she completed her Internal Medicine Internship at Nassau University Medical Center in New York.
Dr. Kaporis completed her dermatology residency at Northeast Regional Medical Center in Missouri, where she served as chief resident. She was in private practice in Mansfield and Arlington, Texas, prior to joining Cooper Clinic in 2013.
She has a passion for helping patients feel confident about their skin and enhancing their natural beauty. Dr. Kaporis is active in numerous local and national dermatologic organizations including the American Society of Dermatologic Surgery. She has been a speaker at national conferences and currently serves as the socioeconomic chair of the Dallas Dermatologic Society.
Dr. Kaporis is married to Aris Tsiakos, MD, a gastroenterologist in private practice. She enjoys skiing and playing tennis with her two young sons.


Australia is a huge country that offers visitors dominant, expansive landscapes. From hills and mountain ranges to picturesque coastside views. Travellers can discover and enjoy more of the fantastic views that Australia has to offer, if they avoid the quickest route from A to B, and embark themselves on breathtaking and adventurous great Australian road trips instead.
Road trips are usually epic and appeal to those explorer genes we all have. It is one of the best ways to see what Australia has to offer and, if kids are included in the trip, a road trip can make the whole travel experience more practical, cost effective and flexible. Aside from the possible 'Are we there yet?' questions from the backseat!
We share some of the best Australian road trip routes to help you plan your driving adventures down under!
It is so easy to misjudge the size of Australia. Afterall, it's just an island, right? However Australia is huge and some Australian travel routes need a fair bit of time. Especially if you are doing the round trip. Others are short and sweet, perfect for a long weekend or week long adventure.
For many travelers, taking a trip along the Great Ocean Road is an Australian rite of passage. The Great Ocean Road is one of Australia's most famous road trips and stretches along the southern coast from Torquay to Allansford, in Victoria. It is one of those trips that are better enjoyed slowly, without rushing.
Take your time to stop and appreciate the many sights and landmarks along the way, or just to stay and enjoy the scenery for a few extra minutes. Don't forget to take your camera with you as there will be some impressive photo opportunities too!
You will get the most from a Great Ocean Road driving trip if you take a few days to do it in, and make sure you go all the way to my beautiful hometown of Portland, less than an hour from the South Australian border. It is a stunning little coastal town at the end of the Great Ocean Road and so many people just miss it.
The Great Ocean Drive is not only famous but also one of the most beautiful Australian coastlines. From Torquay, just an hour away from Melbourne, it stretches 250 kilometers to Portland as it offers stunning coastal scenery, wildlife, hiking, waterfalls and beachside towns.
As one of the world's most scenic drives, it is home to some of Australia's most famous surf meccas. Venture into the pristine rainforest for a bush walk and discover an astonishing variety of native wildlife. Yes! You can spot some native wildlife while you're at it.
December and January are appealing to road trip Victoria if you are into surfing and don't mind chaotic tourist spots or busy roads.
Winter months are quieter and offer not only picturesque views but whale sightings and intense sunsets as well. Check out some of the Great Ocean Road highlights and start planning your ocean view road trip. This is definitely one of the best east coast road trips Australia offers.
Located across the top part of Australia, The Savannah Way is a fantastic road trip that invites travelers to explore the northern section of Outback Queensland. It stretches from Cairns (in Queensland) to Broome, in Western Australia, making it a significant road trip that needs a fair bit of time to enjoy.
Broome to Cairns is around 3700 kilometres although there are alternative shorter routes that won't take you all the way, if you are short on time. Check out the distances here.
Take advantage of the good weather and spend from April to September travelling between Broome and Cairns. As it is the dry season, temperatures are pleasant and all roads are usually open.
Those looking for an adventure, driving a 4WD and with plenty of time to spare (six months at least) should definitely indulge in this long term travel road trip. Adventurous spirits will enjoy this epic journey! The big lap is the ultimate Australian road trip!
As you drive, you will pass by big city lights, verdant green forests, sleepy coastal towns, remote waterholes, the dusty red outback or white-sandy beaches. The Big Lap is a great opportunity to enjoy everything that Australia has to offer.
As the name suggests, this route circumnavigates Australia and follows some 15 thousand kilometres of Highway One, linking seven of the capital cities as you skirt the coastline between Sydney, Brisbane, Gold Coast, Cairns, Darwin, Broome, Perth, Esperance, Adelaide, Melbourne and Hobart.
The sights for this one would be too long to list, but make sure to stop in each of the capital cities and regional gems, discovering what each of the cities has on offer. Every state in Australia has something special to see and do, plus the ferry trip to Tasmania is an adventure in itself!
For some of the highlights around Australia, make sure you check out our Australia travel guide to help you start planning your big lap road trip. However the best way is to just take it each day as it comes.
Doing a drive this big needs at least 6 months, so picking a time is tricky for a trip this long! Avoid the wet season up north, or if you are a summer chaser, avoid the south during the winter because it will be cold! Australia is pretty amazing all year round though.
No list of the most epic Australian road trips would be complete without including a visit to the Outback. And even though you can always take the Stuart Highway between Uluru and Alice Springs, we invite you to take the scenic ride instead along the Red Centre Way.
Driving this route will allow you to discover stunning landscapes, gorges, canyons and amazing hiking trails. Wouldn't it be great to enjoy a lovely, relaxing and recharging walk after driving for so many hours? Take your time and get back to nature!
The Red Centre way takes you on a 1135 km loop from Alice Springs, taking in some dirt roads along the way, through the red centre. If you don't have a 4WD or want to stick to sealed roads, the alternative route is just over 1700 kilometres. You need about 5 or 6 days to complete the loop, but a week or more would allow you to pace yourself.
For more mild temperatures, the best time to drive the Red Centre way is between May and September, when the maximum temperature during the day is typically between 20°C and 30°C.
Tasmania is a beautiful part of Australia that many have compared to the green landscape and rolling hills of the United Kingdom or New Zealand. You won't find any desert in Tassie, but you will find plenty of scenic roads to coast along.
Tasmania has stunning coastlines, mountainscapes, rainforests and quaint cities all equally worth exploring. You can reach Tasmania from the mainland of Australia via ferry if you wish to take your own car, or hire one instead, like we did on our first trip.
The distance between Hobart and Launceston is quite short if you don't want to take in the sights, however we recommend doing it over a week or 2, like our 8 day Hobart to Launceston itinerary so you can enjoy many of the great cities in between.
It actually only takes around 3 hours if you want to go the shortest, most direct route, but don't do that. Trust us, take your time and enjoy exploring this state in detail!
As for time of year, it really depends on what you're wanting out of your Tasmanian road trip. If you are looking for the warmer season, spring or summer are fine, or enjoy a winter escape and head there between May and August when the cold weather kicks in with a force!
When getting ready for a road trip in such a vast country there are some things you should bear in mind in order to make sure you have an enjoyable experience. Overall, it's pretty easy to self drive in Australia.
You simply need to pick your mode of transport, define your route and get going if you want to keep it simple. Although if you are planning a multi day road trip like most of these, you may want to consider whether to book accommodation along the way, take a caravan or tent or hire a campervan.
Whether this is your first road trip or not, distances are definitely something you should consider as they are usually long. Most of the country is sparsely populated, which means that it can be easy to run into trouble if you haven't planned your road stops for fuel (or toilet facilities).
That said, it is advisable that you never set off on any road trip in Australia without having purchased travel insurance for you and car rental damage insurance for your rental car. In both cases, make sure to opt for reliable, experienced and trustworthy provider.
In addition, you should always check how full your cars petrol tank is. Believe me, running out of petrol in the middle of the outback can be a nightmare! To avoid this, make sure that if you see a petrol station and have under a half tank left, fill it up! Even better if you have a phone app with a list of petrol stations on your route before hand so that you have a clear idea of distance from the next one.
And talking once again about adventure, never go off road unless you have a 4×4 vehicle and experience with off road routes. There are plenty of off road tracks in Australia and it can be tempting to drive along them but they are literally off the beaten track and if you experience an issue with your car while on them, you can get into really very serious trouble.
Family road trips are loads of fun but they take a little extra planning! It can be a really budget friendly way of travelling Australia with your kids. To keep them happy, have frequent stops to stretch their legs and give them a change of scenery. Loads of snacks are a must! And of course, entertainment!
Make your own DIY travel activity packs full of fun stuff the kids can do during stops, and make sure you grab our mammoth road trip printables pack that you can print off every time you take a road trip, for fun family friendly activities and games the whole family can get involved with.
Check out our top tips for surviving road trips with kids.
Now you are ready to discover some of the most amazing road trips that Australia has to offer to you.